PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN  by Gschwend, MH et al.
associated with signiﬁcantly lower inpatient ($4,212 vs $7,532,
p < 0.0001), outpatient ($9,501 vs $12,885, p < 0.0001), and
emergency room costs ($82 vs $131, p < 0.0001) and signiﬁcantly
higher drug costs ($6,885 vs $5,936, p < 0.0001). Similarly, the
use of exenatide compared to insulin glargine was also associated
with signiﬁcantly lower diabetes-related inpatient ($2172 vs
$3538, p < 0.0001) and outpatient costs ($2739 vs $3249,
p < 0.0001) and signiﬁcantly higher diabetes-related drug costs
($3160 vs $2424, p < 0.0001). CONCLUSIONS: Use of
exenatide, compared to insulin glargine, was found to be associ-
ated with signiﬁcantly lower annual total direct medical costs and
total diabetes related medical costs even though diabetes related
and total drug costs were higher.
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A COMPARISON OF COSTS AMONG PATIENTS WITHTYPE 2
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OBJECTIVES: Compare costs among patients with type 2 dia-
betes (T2D) treated with either exenatide or sitagliptin, novel
incretin therapies with differing clinical effectiveness.
METHODS: Data from September 2004 to September 2007
were obtained from a large, retrospective, claims database. Data
from intent-to-treat cohorts of adults with T2D who initiated
therapy on either exenatide (N = 1614) or sitagliptin (N = 2482)
and who did not use the other medication in the six-month
follow-up period were examined. Total medical costs and total
diabetes-related medical costs were estimated using stepwise
multivariate regressions. Major cost components were also
examined using either stepwise multivariate regressions or a two-
part model that controlled for the probability of using the
service. Smearing estimates were used to transform estimated log
costs into costs. The analyses controls for the potential impact of
patient demographics, general health, prior resource use, comor-
bidities, and timing of treatment initiation. RESULTS: Initiation
on therapy with exenatide, compared to sitagliptin, was associ-
ated with signiﬁcantly lower total direct medical costs ($8736
vs $9995, p < 0.0001) and total diabetes-related medical
costs ($3841 vs $4002, p < 0.0001). Initiation of therapy with
exenatide compared to sitagliptin was also associated with sig-
niﬁcantly lower inpatient ($745 vs $3624, p < 0.0001), outpa-
tient ($4269 vs $5942, p < 0.0001), drug ($3467 vs $3611,
p < 0.0001) and emergency room costs ($16 vs $44, p < 0.0001).
Similarly, the use of exenatide compared to sitagliptin was
associated with signiﬁcantly lower diabetes-related inpatient
($448 vs $1847, p < 0.0001) and drug costs ($1,677 vs $1743,
p < 0.0001). CONCLUSIONS: Use of exenatide compared to
sitagliptin over six months is associated with signiﬁcantly lower
total direct medical costs and total diabetes-related medical costs.
In addition, exenatide was associated with signiﬁcantly lower
total inpatient, outpatient, drug, and emergency room costs and
signiﬁcantly lower diabetes-related inpatient and drug costs.
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OBJECTIVES: Vildagliptin is an alternative option to glitazones
when treatment intensiﬁcation is required due to loss of glycae-
mic control. Our analysis compares the clinical and cost-utility
effects of these alternative treatments. METHODS: The analysis
uses the Novartis 24-week 2354 study results comparing vilda-
gliptin 50mg BID to pioglitazone 30mg qd. The Shefﬁeld Type 2
Diabetes Model, a patient-level disease management model,
simulates use of therapies, clinical events, treatment of compli-
cations and mortality. Costs, including the £1.13 vildagliptin
daily price and £1.20 for pioglitazone, and quality-of-life (QoL)
effects, including those related to complications and weight effect
of therapies, were aggregated to obtain the incremental cost
per QALY. Uncertainty around key parameters, such as weight
effects and long-term HbA1c trends, was explored using proba-
bilistic sensitivity analysis and scenarios. RESULTS: Assuming
equal long-term HbA1c trends, the point estimate suggests that
vildagliptin is cost effective compared to pioglitazone with a cost
saving of £88 and reduction in QALYs of 0.0006. The marginal
net beneﬁt of vildagliptin compared to pioglitazone is £77 (95%
C.I. -23 to 177) with a 62% likelihood that vildagliptin is cost
effective at a UK notional £20,000 cost/QALY threshold. The
main driver is the cheaper cost of vildagliptin. There is a small
QALY loss due to fewer CHD events with pioglitazone arising
from its superior lipid effects, although this is mitigated by the
QALY gain due to the weight neutrality of vildagliptin. The
long-term HbA1c trends are highly important but uncertain
assumptions, and conclusions about the cost effectiveness could
change if evidence for different trends emerged. CONCLU-
SIONS: The expected differences in lifetime costs and QALYs
between vildagliptin and pioglitazone are small, with consider-
able uncertainty around key parameters. Results suggest a 62%
likelihood that vildagliptin is cost effective compared to piogli-
tazone at a £20,000 cost/QALY threshold assuming similar long-
term HbA1c trends.
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OBJECTIVES: The aim of this analysis was to evaluate the
long-term clinical and economic outcomes associated with
insulin detemir and Neutral Protamine Hagedorn (NPH) insulin
in combination with mealtime insulin aspart in patients with type
1 diabetes in the Belgian, French, German, Italian and Spanish
settings. METHODS: A published and validated computer simu-
lation model of diabetes (CORE Diabetes Model) was used to
make long-term projections of life-expectancy, quality-adjusted
life expectancy and direct medical costs. The analysis was based
on patient characteristics and treatment effects from a 2-year,
multi-national, open-label, randomized, controlled trial. In the
trial, insulin detemir was associated with signiﬁcant improve-
ments in glycemic control after 24 months (HbA1c 7.36% versus
7.58%, mean difference -0.22%, P = 0.022) and major hypogly-
cemic events (69% risk reduction, P = 0.001) versus NPH.
Patients treated with detemir gained less weight (1.7 versus 2.7
kg, P = 0.024). Events were projected for a time horizon of 50
years. RESULTS: Basal-bolus therapy with insulin detemir was
projected to improve quality-adjusted life expectancy by 0.45
years (7.04 versus 6.59 years) versus NPH in the German setting.
Similar improvements were observed in the other countries
(Belgium +0.52, France +0.55, Italy +0.58 and Spain +0.40
years). Insulin detemir was associated with cost savings in
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Belgium (€122,737 versus €134,679), Germany (€74,880 versus
€75,734) and Spain (€44,085 versus €44,661). In France and
Italy, lifetime costs were slightly higher in the detemir arm
(€63,605 versus €63,321 and €92,036 versus €90,139, respec-
tively), leading to incremental cost-effectiveness ratios of €519
and €3256 per QALY gained, respectively. CONCLUSIONS: The
ﬁndings of this analysis suggest that, compared to NPH, insulin
detemir is likely to be dominant in Belgium, Germany and Spain
and highly cost-effective in France and Italy in patients with type
1 diabetes.
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OBJECTIVES: Canadian payers need information comparing
the cost-effectiveness of different starter insulin therapies in
order to make relevant formulary decisions and improve T2DM
patient care. Our analyses compared the cost-effectiveness of
insulin glargine with oral antidiabetic drugs (OADs) to premixed
insulin as starter insulin therapy using published clinical data
(Janka et al, 2005) and modeling the study results to a lifetime
horizon. METHODS: The CORE Diabetes Model was used to
project lifetime clinical and economic outcomes for T2DM
patients. The baseline mean HbA1c (8.85%), age, body mass
index, gender, and duration of diabetes were taken from Janka
et al. Remaining cohort characteristics, transition probabilities,
utilities, direct treatment, and complication costs (from a Cana-
dian Provincial payer perspective) were obtained from published
sources. All costs and clinical outcomes were discounted at 5%
per annum. RESULTS: Average lifetime total direct treatment
and medical costs per patient were CAN$50,328 (+1,769) for
insulin glargine with OADs and CAN$49,555 (+1,940) for pre-
mixed insulin. Discounted life expectancy and quality-adjusted
life years (QALYs) increased by 0.051(+0.286) years and
0.215(+0.216) QALYs, respectively, for insulin glargine with
OADs compared to premixed insulin. The resulting incremental
cost-effectiveness ratios (ICERs) for insulin glargine with OADs
compared to premixed insulin were CAN$15,217/life -year
gained and CAN$3,601/QALY. CONCLUSIONS: Cost-
effectiveness for insulin glargine with OADs compared to pre-
mixed insulin was primarily driven by superior HbA1c reductions
from the Janka et al. study (-1.64% for insulin glargine with
OADs vs. -1.31% for premixed insulin, p = 0.0003) The ICERs
obtained in these analyses provide evidence for the long-term
cost-effectiveness of insulin glargine with OADs compared to
premixed insulin as an initial insulin therapy for Canadians with
T2DM.
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OBJECTIVES: Canadian payers need information comparing the
cost-effectiveness of long-acting insulin analogues (LAIAs) in
order to make relevant formulary decisions. Our analyses com-
pared the cost-effectiveness of insulin glargine with insulin
detemir using published clinical data for both T1DM (Pieber
et al, 2007) and T2DM (Rosenstock et al, 2008). METHODS:
The CORE Diabetes Model was used to project lifetime clinical
and economic outcomes for T1DM and T2DM patients in sepa-
rate analyses. For T1DM, baseline mean HbA1c (8.8%), age,
body mass index, gender, and duration of diabetes were taken
from Pieber et al. For T2DM, baseline mean HbA1c (8.6%), age,
body mass index, gender, race/ethnicity, and duration of diabetes
were taken from Rosenstock et al. Remaining cohort character-
istics, transition probabilities, utilities, direct treatment, and
complication costs (from a Canadian Provincial payer perspec-
tive) were obtained from published sources for both T1DM and
T2DM analyses. All costs and clinical outcomes in both analyses
were discounted at 5% per annum. RESULTS: For T1DM,
detemir was found to have higher overall direct medical costs
(CAN$2667  4785) than glargine with a slight increase
in quality-adjusted life years (QALYs, 0.053  0.507). The
resulting incremental cost-effectiveness ratio (ICER) was
CAN$50,569/QALY for glargine compared with detemir in
T1DM. For T2DM, detemir was found to have higher overall
direct medical costs (CAN$5748  2881) than glargine with a
very slight decrease in quality-adjusted life years (QALYs,
0.005  0.259). Glargine demonstrated lower direct medical
costs and a slight improvement in QALYs compared with detemir
and is therefore a dominant strategy in T2DM. CONCLU-
SIONS: Insulin glargine demonstrated cost-effectiveness in
T1DM, consistent with current Canadian standards for health
technology assessment, and was a dominant treatment strategy in
T2DM for Canada.
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OBJECTIVES: Reduced health-related quality of life (HRQoL)
is a pronounced complication in short individuals with Growth
Hormone Deﬁciency (GHD). Current treatment options for
GHD children are limited; however, somatropin has been shown
to normalise height in childhood and adolescence compared
with no treatment. The aim of this study was to establish
whether somatropin is a cost-effective treatment for GHD
children compared with no treatment. METHODS: A cost-
effectiveness model estimated the costs and health beneﬁts over
the lifetime of GHD children. Treatment efﬁcacy was based on
Height standard deviation scores (HSDS). A Swedish health care
perspective was used. Unit costs (SEK; 2008) were obtained
from ofﬁcial sources. A 3.0% discount rate was used. Clinical
data (height, dosing and treatment duration) were obtained from
a systematic literature review (only studies with n > 300). Utility
data was derived from a published study assessing the relation
between HSDS and HRQOL. Sensitivity analyses were con-
ducted to assess the degree of uncertainty. RESULTS: Start
HSDS was -2.8 (SD 0.8) and ﬁnal HSDS was -1.5 (SD 0.8) with
somatropin treatment. Untreated children gained no HSDS. The
mean somatropin dose was 0.023 mg/kg/day over a duration of
5.1 years (SD 1.8) Over a patient’s lifetime, somatropin was
associated with a gain of 2.3 quality adjusted life years (QALYs).
Somatropin was associated with an incremental cost per QALY
of 342,592 SEK compared with no treatment. Probabilistic sen-
sitivity analysis, in which all parameters within the model were
varied, showed that there was a high probability that somatro-
pin was cost effective compared with no treatment, based on
a willingness to pay threshold of 500,000 SEK per QALY.
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